Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GRI Bio, Inc. stock logo
GRI
GRI Bio
$1.41
-2.1%
$1.54
$1.10
$30.43
$3.62M-1.61220,146 shs39,525 shs
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$2.24
-2.6%
$2.80
$1.29
$7.12
$12.07M2.245,578 shs8,166 shs
NextCure, Inc. stock logo
NXTC
NextCure
$5.22
$5.21
$2.69
$19.80
$13.96M1.2529,296 shs4,582 shs
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
$1.12
+1.0%
$1.14
$0.70
$2.44
$12.85M0.4218,964 shs9,272 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GRI Bio, Inc. stock logo
GRI
GRI Bio
+2.86%-2.04%-27.64%+9.92%-83.36%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
-2.34%-10.85%-18.15%+22.99%-20.69%
NextCure, Inc. stock logo
NXTC
NextCure
+1.75%-0.76%-15.40%-11.59%-72.98%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
+2.28%-1.32%-5.46%-24.50%-36.44%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
GRI Bio, Inc. stock logo
GRI
GRI Bio
2.0506 of 5 stars
3.52.00.00.01.50.01.3
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
0.4749 of 5 stars
0.05.00.00.01.50.00.0
NextCure, Inc. stock logo
NXTC
NextCure
3.9409 of 5 stars
3.33.00.04.30.01.71.3
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
0.1424 of 5 stars
0.03.00.00.00.00.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GRI Bio, Inc. stock logo
GRI
GRI Bio
3.00
Buy$22.001,460.28% Upside
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
0.00
N/AN/AN/A
NextCure, Inc. stock logo
NXTC
NextCure
2.67
Moderate Buy$25.50388.51% Upside
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest GRI, IMCC, NXTC, and TXMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/15/2025
NextCure, Inc. stock logo
NXTC
NextCure
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOverweight ➝ Overweight$36.00 ➝ $15.00
7/8/2025
NextCure, Inc. stock logo
NXTC
NextCure
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
7/1/2025
NextCure, Inc. stock logo
NXTC
NextCure
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00
6/11/2025
GRI Bio, Inc. stock logo
GRI
GRI Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/27/2025
GRI Bio, Inc. stock logo
GRI
GRI Bio
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$40.00 ➝ $34.00
(Data available from 8/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GRI Bio, Inc. stock logo
GRI
GRI Bio
N/AN/AN/AN/A$1.32 per shareN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$39.44M0.30N/AN/A$0.56 per share4.00
NextCure, Inc. stock logo
NXTC
NextCure
N/AN/AN/AN/A$11.82 per shareN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
$1.76M7.37N/AN/A$2.36 per share0.48
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GRI Bio, Inc. stock logo
GRI
GRI Bio
-$8.21M-$11.56N/AN/AN/AN/A-327.62%-191.40%11/13/2025 (Estimated)
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
-$7.72M-$0.54N/AN/AN/A-4.19%-59.80%-5.15%11/12/2025 (Estimated)
NextCure, Inc. stock logo
NXTC
NextCure
-$55.65M-$25.82N/AN/AN/AN/A-106.62%-85.20%11/6/2025 (Estimated)
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
-$2.18MN/A0.00N/A-17.94%-2.01%-1.40%11/10/2025 (Estimated)

Latest GRI, IMCC, NXTC, and TXMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
GRI Bio, Inc. stock logo
GRI
GRI Bio
-$1.31-$1.31N/A-$1.31N/AN/A
8/12/2025Q2 2025
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
-$0.1367-$0.0653+$0.0714-$0.07$12.88 million$9.21 million
8/12/2025Q2 2025
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/A$0.05N/A$0.05N/A$0.95 million
8/7/2025Q2 2025
NextCure, Inc. stock logo
NXTC
NextCure
-$4.62-$11.29-$6.67-$11.29N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
GRI Bio, Inc. stock logo
GRI
GRI Bio
N/AN/AN/AN/AN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
N/AN/AN/AN/AN/A
NextCure, Inc. stock logo
NXTC
NextCure
N/AN/AN/AN/AN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GRI Bio, Inc. stock logo
GRI
GRI Bio
N/A
2.41
2.41
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
0.32
0.72
0.62
NextCure, Inc. stock logo
NXTC
NextCure
N/A
3.71
3.71
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/A
2.89
2.89

Institutional Ownership

CompanyInstitutional Ownership
GRI Bio, Inc. stock logo
GRI
GRI Bio
33.95%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
7.68%
NextCure, Inc. stock logo
NXTC
NextCure
42.65%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
30.74%

Insider Ownership

CompanyInsider Ownership
GRI Bio, Inc. stock logo
GRI
GRI Bio
0.87%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
N/A
NextCure, Inc. stock logo
NXTC
NextCure
13.30%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
2.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
GRI Bio, Inc. stock logo
GRI
GRI Bio
12.52 million2.49 millionNot Optionable
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
3405.25 millionN/ANot Optionable
NextCure, Inc. stock logo
NXTC
NextCure
902.68 million2.32 millionOptionable
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
42011.57 million11.31 millionOptionable

Recent News About These Companies

TherapeuticsMD: Q2 Earnings Snapshot
TherapeuticsMD Shifts Focus with Lower Q3 Losses
TherapeuticsMD Reports Reduced Losses Amid Strategic Shift
TherapeuticsMD Announces Third Quarter 2024 Financial Results
TherapeuticsMD (NASDAQ:TXMD) Stock, Option Chain

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
GRI Bio stock logo

GRI Bio NASDAQ:GRI

$1.41 -0.03 (-2.08%)
As of 04:00 PM Eastern

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

IM Cannabis stock logo

IM Cannabis NASDAQ:IMCC

$2.24 -0.06 (-2.61%)
Closing price 03:59 PM Eastern
Extended Trading
$2.28 +0.04 (+1.79%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.

NextCure stock logo

NextCure NASDAQ:NXTC

$5.22 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$5.20 -0.01 (-0.29%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

TherapeuticsMD stock logo

TherapeuticsMD NASDAQ:TXMD

$1.12 +0.01 (+0.99%)
Closing price 03:55 PM Eastern
Extended Trading
$1.12 +0.00 (+0.36%)
As of 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.